Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium

Behavior/Comportment/Personality (BEHAV) and Language (LANG) domains were added to the Clinical Dementia Rating (CDR®) for improving evaluation of patients with frontotemporal lobar degeneration (FTLD) (CDR® plus NACC FTLD).

• Publication year

  2020

• Venue

  Alzheimer's & Dementia

• Publication date

  2020-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jalz.2019.05.013PMID 31477517PMCID PMC6949373
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Frontotemporal Lobar Degeneration-Modified Clinical Dementia Rating (FTLD-CDR) Scale and Frontotemporal Dementia Rating Scale (FRS) Correlation With Regional Brain Perfusion in a Series of FTLD Patients.

  2017cited by this paper
• Utility of the Spanish version of the FTLD-modified CDR in the diagnosis and staging in frontotemporal lobar degeneration.

  2014cited by this paper
• Criteria for the diagnosis of corticobasal degeneration

  2013cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Language and behavior domains enhance the value of the clinical dementia rating scale

  2011cited by this paper
• Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

  2011cited by this paper
• Classification of primary progressive aphasia and its variants

  2011cited by this paper
• The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Clinicopathological correlations in corticobasal degeneration

  2011cited by this paper
• Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy.

  2010cited by this paper
• The FTLD‐modified Clinical Dementia Rating scale is a reliable tool for defining disease severity in Frontotemporal Lobar Degeneration: evidence from a brain SPECT study

  2010cited by this paper
• Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia

  2008cited by this paper
• Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia

  2008cited by this paper
• Development of methodology for conducting clinical trials in frontotemporal lobar degeneration.

  2008cited by this paper
• Frontal presentation in progressive supranuclear palsy

  2007cited by this paper
• Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan

  2007cited by this paper
• A clinical rating scale for progressive supranuclear palsy.

  2007cited by this paper
• Behavioral features in semantic dementia vs other forms of progressive aphasias

  2006cited by this paper
• The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers

  2006cited by this paper
• The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment

  2005cited by this paper
• The evolution and pathology of frontotemporal dementia.

  2005cited by this paper
• The natural history of temporal variant frontotemporal dementia

  2005cited by this paper
• Primary progressive aphasia: Diagnosis, varieties, evolution

  2003cited by this paper
• Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory.

  2000cited by this paper
• El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis

  2000cited by this paper
• Mild Cognitive Impairment Clinical Characterization and Outcome

  1999cited by this paper
• Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)

  1996cited by this paper
• The Clinical Dementia Rating (CDR)

  1993cited by this paper
• A New Clinical Scale for the Staging of Dementia

  1982cited by this paper
• Measurement of functional activities in older adults in the community.

  1982cited by this paper

• Individualized Atrophy-Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed-Effects Modeling.

  2026cites this paper
• The role of bilingualism on functional decline and neurodegeneration in distinct ADRD clinical syndromes

  2025cites this paper
• MRI‐DTI Biomarkers Along the Continuum of Behavioral Variant Frontotemporal Dementia

  2025cites this paper
• Longitudinal functional network connectivity changes across the clinical stages of C9orf72 hexanucleotide repeat expansion carriers

  2025cites this paper
• Preclinical and Prodromal Frontotemporal Dementia: Challenges and Opportunities

  2025cites this paper
• Development and validation of the TabCAT-EXAMINER: A tablet-based executive functioning battery for research and clinical trials

  2025influential citation
• Integrating a motor domain enhances disease severity scales in an FTD‐ALS spectrum cohort

  2025cites this paper
• Cortical microstructure in familial frontotemporal dementia associated with MAPT, GRN, and C9orf72 pathogenic variants: Looking beyond atrophy

  2025cites this paper
• Multiparametric MRI-based biomarkers in the non-fluent and semantic variants of primary progressive aphasia

  2025cites this paper
• Mini social cognition and emotional assessment: Diagnostic performance and neural correlates in behavioural-variant frontotemporal dementia.

  2025cites this paper
• Hyperorality in Frontotemporal Dementia: How Psychiatric and Neural Correlates Change During the Disease Course.

  2025cites this paper
• Neuropsychiatric symptoms cluster and fluctuate over time in behavioral variant frontotemporal dementia

  2025cites this paper
• Montreal Cognitive Assessment vs the Mini-Mental State Examination as a Screening Tool for Patients With Genetic Frontotemporal Dementia

  2025cites this paper
• Hyperorality in Frontotemporal Dementia: How Psychiatric and Neural Correlates Change Across the Disease Course

  2024cites this paper
• Extending the phenotypic spectrum assessed by the CDR plus NACC FTLD in genetic frontotemporal dementia

  2024cites this paper
• Semantic knowledge of social norms in frontotemporal dementia patients with either predominant frontal or temporal lobe atrophy.

  2024cites this paper
• Association of Initial Side of Brain Atrophy With Clinical Features and Disease Progression in Patients With GRN Frontotemporal Dementia

  2024cites this paper
• The TabCAT-EXAMINER Executive Functioning Battery: Development and validation of a composite score in aging and neurodegenerative cohorts

  2024influential citation
• Gene-Specific Effects on Brain Volume and Cognition of TMEM106B in Frontotemporal Lobar Degeneration

  2024cites this paper
• Neuropsychiatric Symptoms Cluster and Fluctuate Over Time in Behavioral Variant Frontotemporal Dementia

  2024cites this paper
• A framework for translating tauopathy therapeutics: Drug discovery to clinical trials

  2024cites this paper
• Impairments in knowledge of social norms in presymptomatic, prodromal, and symptomatic frontotemporal dementia

  2024cites this paper
• Predictors of Care Home Admission and Survival Rate in Patients With Syndromes Associated With Frontotemporal Lobar Degeneration in Europe

  2024cites this paper
• Cognitive dispersion and its functional relevance in behavioral variant frontotemporal dementia and prodromal behavioral variant frontotemporal dementia.

  2024cites this paper
• Non-motor symptoms in patients with amyotrophic lateral sclerosis: current state and future directions

  2024cites this paper
• Symptomatic progression of frontotemporal dementia with the TARDBP I383V variant

  2024cites this paper
• Sex Differences in the Severity and Progression of Neuropsychiatric Symptoms Across Different Dementia Types.

  2024cites this paper
• Theme 11 - Cognitive and Psychological Assessment and Support

  2023cites this paper
• Neuropsychiatric symptoms in genetic frontotemporal dementia: developing a new module for Clinical Rating Scales

  2023cites this paper
• The ScreeLing: Detecting Semantic, Phonological, and Syntactic Deficits in the Clinical Subtypes of Frontotemporal and Alzheimer’s Dementia

  2023cites this paper
• Genetic forms of primary progressive aphasia within the GENetic Frontotemporal dementia Initiative (GENFI) cohort: comparison with sporadic primary progressive aphasia

  2023influential citation
• Association of cortical and subcortical microstructure with disease severity: impact on cognitive decline and language impairments in frontotemporal lobar degeneration

  2023cites this paper
• Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progression.

  2023cites this paper
• Feasibility and acceptability of remote smartphone cognitive testing in frontotemporal dementia research

  2023cites this paper
• Prodromal language impairment in genetic frontotemporal dementia within the GENFI cohort.

  2023cites this paper
• Network Connectivity Alterations across the MAPT Mutation Clinical Spectrum

  2023cites this paper
• Moral reasoning through the eyes of persons with behavioral variant frontotemporal dementia

  2023cites this paper
• Longitudinal changes in qualitative aspects of semantic fluency in presymptomatic and prodromal genetic frontotemporal dementia

  2023cites this paper
• Development of a Speech-based Composite Score for Remotely Quantifying Language Changes in Frontotemporal Dementia

  2023cites this paper
• Utility of the Japanese version of the Clinical Dementia Rating® plus National Alzheimer's Coordinating Centre Behaviour and Language Domains for sporadic cases of frontotemporal dementia in Japan

  2023cites this paper
• Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development

  2022cites this paper
• Portuguese version of the CDR plus NACC FTLD: Validation studies

  2022cites this paper
• Loss of brainstem white matter predicts onset and motor neuron symptoms in C9orf72 expansion carriers: a GENFI study

  2022cites this paper
• Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales

  2022cites this paper
• Brain Metabolic Profile in Presymptomatic GRN Carriers Throughout a 5-Year Follow-up

  2022cites this paper
• Temporal order of clinical and biomarker changes in familial frontotemporal dementia

  2022cites this paper
• Hyperorality in Frontotemporal Dementia: Cognitive and Psychiatric Symptom Profiles in Early-Stage Disease

  2022cites this paper
• How can we define the presymptomatic C9orf72 disease in 2022? An overview on the current definitions of preclinical and prodromal phases.

  2022cites this paper
• Mindfulness-Based Stress Reduction in Pre-symptomatic Genetic Frontotemporal Dementia: A Pilot Study

  2022cites this paper
• Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study

  2022influential citation
• Proposed research criteria for prodromal behavioural variant frontotemporal dementia

  2022cites this paper
• New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia

  2022cites this paper
• Biological basis and psychiatric symptoms in frontotemporal dementia

  2022cites this paper
• Language impairment in the genetic forms of behavioural variant frontotemporal dementia

  2022cites this paper
• Characterization of dementia with Lewy bodies (DLB) and mild cognitive impairment using the Lewy body dementia module (LBD‐MOD)

  2021cites this paper
• Uniform data set language measures for bvFTD and PPA diagnosis and monitoring

  2021cites this paper
• An MRI-based strategy for differentiation of frontotemporal dementia and Alzheimer’s disease

  2021cites this paper
• The Frontotemporal Dementia Prevention Initiative: Linking Together Genetic Frontotemporal Dementia Cohort Studies.

  2021cites this paper
• Efficacy and safety of blood derivatives therapy in Alzheimer’s disease: a systematic review and meta-analysis

  2021cites this paper
• Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia

  2021cites this paper
• The contribution of behavioral features to caregiver burden in FTLD spectrum disorders

  2021cites this paper
• Prodromal frontotemporal dementia: clinical features and predictors of progression

  2021cites this paper
• Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study

  2021cites this paper
• A latent variable approach to measuring bridging social capital and examining its association to older adults’ cognitive health

  2021cites this paper
• Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies

  2021cites this paper
• A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia

  2021cites this paper
• Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency

  2021cites this paper
• Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort

  2021cites this paper
• The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort

  2021cites this paper
• Functional Disabilities and Psychiatric Symptoms in Primary Progressive Aphasia.

  2021cites this paper
• Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia.

  2021cites this paper
• Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants

  2020cites this paper
• Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia

  2020cites this paper
• Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort

  2020cites this paper
• Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium

  2020cites this paper
• New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

  2020cites this paper
• Parkinsonism in frontotemporal dementias.

  2019cites this paper
• Gene-specific effects on brain volume and cognition of Gene-specific effects on brain volume and cognition of TMEM106B in frontotemporal lobar degeneration TMEM106B in frontotemporal lobar degeneration

  year unknowncites this paper